A Focus on Lung Cancers

Thursday, April 6, 2023 | 12-4 p.m. PDT
Hybrid | Virtual and San Diego, CA

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for lung cancer.

Register Now

Program Organizers

Kasey_Bamel.png

Kasey Bamel, DNP
University of California San Diego Moores Cancer Center


Christopher Coyne, MD, MPH
University of California San Diego Health


Misako Nagasaka, MD, PhD
UCI Irvine


Sandip P. Patel, MD
University of California San Diego Moores Cancer Center

Program Agenda

11:55–12 p.m.

 

Welcome

12-12:30 p.m.

 

Overview of Frontline IO Options in NSCLC

Sandip P. Patel, MD - University of California San Diego Moores Cancer Center

12:301 p.m.

 

Neoadjuvant and Adjuvant IO Strategies in NSCLC

Misako Nagasaka, MD, PhD – UC Irvine

11:30 p.m.

 

Managing Symptom Assessments

Kasey Bamel, DNP -  University of California San Diego Moores Cancer Center

1:30–2 p.m.

 

Assessment and Initial Intervention in the Emergency Room

Christopher Coyne, MD, MPH - University of California San Diego Health

2-2:30 p.m.

 

Break

2:30–3:10 p.m.

 

Emerging Treatments, Emerging Toxicities

Sandip P. Patel, MD - University of California San Diego Moores Cancer Center

Christopher Coyne, MD, MPH - University of California San Diego Health

3:104 p.m.

 

Faculty Panel

Kasey Bamel, DNP -  University of California San Diego Moores Cancer Center

Christopher Coyne, MD, MPH - University of California San Diego Health

Misako Nagasaka, MD, PhD - UCI Irvine

Sandip P. Patel, MD - University of California San Diego Moores Cancer Center

Program Details

Venue information

Hilton San Diego Bayfront

1 Park Blvd, San Diego, CA 92101

Rising above the San Diego Bay and steps from the Gaslamp Quarter and Petco Park, Hilton San Diego Bayfront is the signature SoCal resort. Enjoy a tailored, urban coastal experience with bright and unparalleled views in every guest room, relaxing amenities, and locally-inspired dining.

Program Learning Objectives

  • Summarize recent updates in cancer immunotherapy for lung cancer and toxicity management for key disease states.
  • Implement cancer immunotherapy for lung cancer into clinical practice appropriately.
  • Describe management approaches for difficult or refractory immune-related adverse events.
  • Describe the use of biomarkers to select appropriate cancer immunotherapies for lung cancer patients.

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

Accreditation Information

Joint Accreditation Statement

thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

ABIM_Logo.jpg

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



Physician Continuing Medical Education

PACE designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

PACE designates this continuing education activity for 3.5 contact hour(s) (0.35 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

Disclosures and ADA Info

Disclosure of Conflicts of Interest

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact SITC Staff prior to the live event at (414) 271-2456 or via email education@sitcancer.org.

Avoid Fraudulent ACI Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.